Mixed Tech and Biotech Outlook: RADCOM Lowers Guidance as Vericel Raises Targets and Buyback

Key Facts

1RADCOM announced preliminary Q2 revenue and lowered its full-year 2026 outlook due to customer deployment delays.

2Vericel raised its full-year 2026 revenue guidance to $330-$340 million and authorized a $200 million share repurchase program.

Amid diverging corporate responses to supply chain hurdles and sector demand, RADCOM Ltd. announced preliminary Q2 results and lowered its full-year 2026 guidance. The company attributed the revision to customer deployment delays caused by rising component costs and supply constraints, adjusting its annual revenue target to a range of $57 million to $63 million. Management emphasized that these dynamics are related to timing issues rather than a fundamental shift in market demand.

In contrast, Vericel Corporation demonstrated robust growth driven by strong demand in sports medicine and burn care markets, raising its full-year 2026 revenue guidance to between $330 million and $340 million. Per market data, VCEL shares closed at $46.71 on July 28, 2026, bolstered by the authorization of a significant $200 million share repurchase program, signaling strong management confidence in the company's financial trajectory relative to its peers.

Investors are closely monitoring RDCM, which stood at $13.08 at the close of July 28, 2026, ahead of its formal earnings release scheduled for August 12, 2026. With no major upcoming sector-specific catalysts in the immediate calendar, market attention remains on supply chain recovery, particularly following recent U.S. Manufacturing PMI data which printed at 53.8.